GlassScriptPhysician profile
Abdul Shahein
NPI 1811236714
$1,297.52
in general payments reported to CMS, 2019-2025
21 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.07 · 2022: $129 · 2023: $363 · 2024: $358 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $226.71 | 2023-2025 | Sucraid |
| Genzyme Corporation | $210.26 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $200.29 | 2024 | Bylvay |
| Stryker Corporation | $140.68 | 2025 | Aequalis Perform |
| Regeneron Healthcare Solutions, INC. | $89.27 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $72.10 | 2025 | Tremfya |
| Travere Therapeutics, INC. | $41.45 | 2022 | |
| Acadia Pharmaceuticals INC | $38.15 | 2024-2025 | Daybue |
| Abbvie INC. | $38.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.18 | 2025 | Eohilia |
| Ironwood Pharmaceuticals, INC | $32.20 | 2024 | |
| Mauna Kea Technologies, INC. | $24.98 | 2025 | |
| Pharming Healthcare, INC. | $24.24 | 2022 | |
| Alcresta Therapeutics, INC. | $22.10 | 2023 | Relizorb |
| Coloplast Corp | $21.31 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $18.91 | 2023 | Bylvay |
| Rhythm Pharmaceuticals, INC. | $17.07 | 2021 | |
| Biocon Biologics INC | $16.04 | 2025 | Yesintek |
| Mirum Pharmaceuticals, INC. | $15.30 | 2025 | Cholbam, Chenodal, Livmarli |
| Applied Medical Technology INC | $14.25 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Shahein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.